- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Combined Effect of Not Expanding Medicaid and Losing Marketplace Assistance
As of April 2015, 21 states have chosen not to expand Medicaid eligibility under the Affordable Care Act. All but one of those states have also chosen to rely on federally facilitated marketplaces.
As of April 2015, 21 states have chosen not to expand Medicaid eligibility under the Affordable Care Act. All but one of those states have also chosen to rely on federally facilitated marketplaces.
If the Supreme Court finds for the plaintiff in King v. Burwell, the combined effect of not expanding Medicaid and losing federal support for marketplace coverage for the low-income population would be dramatic for the 20 states affected by both decisions.
In total, 9.8 million people would be uninsured who would have otherwise been insured. Assuming that marketplace financial assistance is not replaced and assuming those states do not choose to expand Medicaid, the total loss in federal spending from 2016 to 2025 would be $721 billion.
Read the full brief at the Urban Institute: http://urbn.is/1Jhwe0X
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
